Printed From:


Consider prescribing DUPIXENT for your patients with inadequately controlled severe asthma

  • DUPIXENT is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with Type 2 inflammation characterised by raised blood eosinophils (EOS) and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with high-dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment1
DUPIXENT is a fully human monoclonal antibody that binds specifically to the IL-4Rα subunit and inhibits IL-4 and IL-13 signalling1

The impact of severe asthma can differ from person to person2


Clinical profile

  • 35 years old
  • Severe asthma
  • ≥5 annual exacerbations
  • Current treatment: daily high-dose inhaled corticosteroid (ICS) plus long-acting ß2-agonist (LABA)
Blood EOS level Total IgE Baseline FeNO Lung function (FEV1)
150 cells/µL 35 IU/mL 35 ppb 60%


I am fed up with taking so many medicines with no improvement

  • Frequent absences from work stopping her from progressing her career
  • Fed up with the amount of medications she has taken for her severe asthma with little or no effect
  • Finds it difficult to care for her three young children and always needs support from partner and other family members with childcare
  • Tired and angry with lack of sleep as woken up numerous times at night

Patients like Julie can benefit
from treatment with DUPIXENT

  • DUPIXENT significantly reduces asthma exacerbations, improves lung function and improves quality of life, compared to placebo3–6
  • DUPIXENT has a long-term safety profile observed in clinical studies of adults and adolescents1


DUPIXENT can be administered via
a pre-filled pen or a syringe1

A&E, accident and emergency; EOS, eosinophils; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; IgE, Immunoglobulin E; IL, interleukin; IU, international units; LABA, long-acting ß2-agonist; ppb, parts per billion; R, receptor.


  1. Sanofi Genzyme. Dupixent Summary of Product Characteristics, September 2021.
  2. Asthma UK. What is severe asthma? Available at: Date accessed: November 2021.
  3. Bourdin A, et al. Allergy. 2021;76(1):269–280.
  4. Sanofi Data on file. REF-98937. October 2020.
  5. Rabe KF, et al. N Engl J Med. 2018;378(26):2475–2485.
  6. Bourdin A, et al. Allergy. 2021;76(1):269–280. Supplementary Appendix S1.